| SKU: | |
|---|---|
| Stock: | 3490 |
| Cost: | $3.95 |
What is the current price of Alector stock?
Since then, ALEC stock has decreased by 29.7% and is now trading at $17.51. View which stocks have been most impacted by COVID-19. When is Alector's next earnings date? Alector is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022. View our earnings forecast for Alector.
Is Alder Biopharmaceuticals efficiently growing its dividend?
Alder Biopharmaceuticals does not have a long track record of dividend growth. In the past three months, Alder Biopharmaceuticals insiders have not sold or bought any company stock. 15.40% of the stock of Alder Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Where can I buy Alec shares?
Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How did Alector (Alec) perform in the Q4 earnings?
Alector, Inc. (NASDAQ:ALEC) posted its quarterly earnings data on Thursday, November, 4th. The company reported $1.49 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $1.95. The company had revenue of $182.41 million for the quarter, compared to analyst estimates of $407.41 million.
How were Alder Biopharmaceuticals' earnings last quarter?
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) issued its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.0...
Who are Alder Biopharmaceuticals' key executives?
Alder Biopharmaceuticals' management team includes the following people: Dr. John A. Latham , Co-Founder & Chief Scientific Officer (Age 59) Mr....
Who are some of Alder Biopharmaceuticals' key competitors?
Some companies that are related to Alder Biopharmaceuticals include Sarepta Therapeutics (SRPT) , Perrigo (PRGO) , Intra-Cellular Therapies (ITC...
What other stocks do shareholders of Alder Biopharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVD...
What is Alder Biopharmaceuticals' stock symbol?
Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
What is Alder Biopharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $18.88.
How much money does Alder Biopharmaceuticals make?
Alder Biopharmaceuticals (NASDAQ:ALDR) has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharma...
How many employees does Alder Biopharmaceuticals have?
Alder Biopharmaceuticals employs 202 workers across the globe.
What is Alder Biopharmaceuticals' official website?
The official website for Alder Biopharmaceuticals is www.alderbio.com .
How were Alder Biopharmaceuticals' earnings last quarter?
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.01. View Alder Biopharmaceuticals' earnings history.
Who are some of Alder Biopharmaceuticals' key competitors?
Some companies that are related to Alder Biopharmaceuticals include Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Arena Pharmaceuticals (ARNA), Zai Lab (ZLAB), Perrigo (PRGO), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Intra-Cellular Therapies (ITCI), Ionis Pharmaceuticals (IONS), Galapagos (GLPG), Hypera (HYPMY) and ACADIA Pharmaceuticals (ACAD). View all of ALDR's competitors..
What other stocks do shareholders of Alder Biopharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), (CPXX) (CPXX), Micron Technology (MU), (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT) and Celldex Therapeutics (CLDX).
What is Alder Biopharmaceuticals' stock symbol?
Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
What is Alder Biopharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $18.88.
How much money does Alder Biopharmaceuticals make?
Alder Biopharmaceuticals has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296.43 million in net income (profit) each year or ($4.87) on an earnings per share basis.
What is Alder Biopharmaceuticals' official website?
The official website for Alder Biopharmaceuticals is www.alderbio.com.
Where is Aldebaran located?
Aldebaran acquired the Rio Grande copper-gold project located in Salta Province, Argentina from Regulus along with several other early-stage projects in Argentina. Aldebaran also has the right to earn up to an 80% interest in the Altar copper-gold project in San Juan Province, Argentina from Sibanye Stillwater.
When is the Altar Resource Estimate effective?
Altar Resource Estimate The Altar Resource Estimate has an effective date of March 22, 2021 and was completed by Independent Mining Consultants (IMC) out of Tucson, Arizona.
What is OTC market?
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Aldebaran Resources Inc. (TSX-V: ALDE) (OTCQX: ADBRF), a mineral exploration company, has qualified to trade on the OTCQX® Best Market. Aldebaran Resources Inc. upgraded to OTCQX from the Pink® market.
Where is the Altar Copper Gold Project located?
("Aldebaran" or the "Company", ALDE TSX.V) is pleased to announce the filing on SEDAR of an updated National Instrument 43-101 Mineral Resource Estimate (the “Altar Resource Estimate”) on the Altar copper-gold project located in San Juan province, Argentina (see news release dated March 22, 2021). The Altar Resource Estimate has an effective date of March 22, 2021 and was completed by Independent Mining Consultants (IMC) out of Tucson, Arizona at the request of Aldebaran. The report titled, "Technical Report, Estimated Mineral Resources, Altar Project, San Juan Province, Argentina" has been filed on the SEDAR website at www.sedar.com and will be posted on the Company’s website at www.aldebaranesources.com. For further information, please consult our website at www.aldebaranresources.com or contact: Laura BrangwinInvestor Relations ManagerPhone: +1 646 583-1404 Email: [email protected] About Aldebaran Resources Inc. Aldebaran is a mineral exploration company that was spun out of Regulus Resources Inc. in 2018 and has the same core management team. Aldebaran acquired the Rio Grande copper-gold project located in Salta Province, Argentina from Regulus along with several other early-stage projects in Argentina. Aldebaran also has the right to earn up to an 80% interest in the Altar copper-gold project in San Juan Province, Argentina from Sibanye Stillwater. Altar hosts several large porphyry copper-gold systems with mineralization currently defined in six distinct zones. The Altar project forms part of a more regional cluster of world-class porphyry copper deposits, which includes Los Pelambres (Antofagasta Minerals), El Pachon (Glencore), and Los Azules (McEwen Mining). A total of 259 drill holes (119,052 m) have been completed at Altar between 1995 and 2020. Aldebaran’s primary focus is the Altar project with a view to discovering new zones with higher-grade mineralization. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
When will the TSX Venture Exchange close?
The Company intends to continue to drill until the end of the field season, which is typically in May. The Offering is scheduled to close on or about April 29, 2021, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals of the TSX Venture Exchange.
Is Altar Central a gold or silver deposit?
Altar Central and Altar East are separated into supergene copper (secondary sulphide) and hypogene copper-gold (primary sulphide) mineralization. The QDM Gold deposit is categorized as a separate resource as it is located approximately 3 km west from Altar Central and is primarily a gold-silver deposit.
About Alector
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies.
Headlines
Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know - Nasdaq
Alector (NASDAQ:ALEC) Frequently Asked Questions
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alector stock. View analyst ratings for Alector or view top-rated stocks.
Alector Reports Fourth Quarter and Full Year 2021 Financial Results
CTAD and SITC presentations in fourth quarter highlight progress across immuno-neurology and immuno-oncology portfolio Over $900 million in pro forma cash, cash equivalents and investments supports execution of clinical, research and operational goals Steady continued enrollment in progranulin franchise clinical trials for AL001 and AL101 and TREM2-targeting program for Alzheimer's disease, AL002 SOUTH SAN FRANCISCO, Calif., Feb.
Will Alector (ALEC) Report Negative Q4 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
International Petroleum Corporation Announces Results of Share Repurchase Program
TORONTO, Ontario, Feb. 14, 2022 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 441,693 IPC common shares (ISIN: CA46016U1084) during the period of February 7 to 11, 2022 under the previously announced share repurchase program.
Edoc Acquisition Corp. Reminds Shareholders to Vote in Favor of Extension Amendment
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp.
EDOC Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination
Victor, NY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp.
EDOC Acquisition Corp. Announces Sponsor Approval of Extension of Deadline to Complete Business Combination
Victor, NY, Nov. 09, 2021 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp.
Do Insiders Own Lots Of Shares In Edoc Acquisition Corp. (NASDAQ:ADOC)?
If you want to know who really controls Edoc Acquisition Corp. ( NASDAQ:ADOC ), then you'll have to look at the makeup...
Edoc Acquisition Corp. Receives Expected Notice from Nasdaq Regarding Delayed Annual Report
New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp.
